A Rosolen
Impact in
-
- Lymphoma Diagnosis and Treatment
- Immunology top 10%
- Immune Cell Function and Interaction
Papers in
-
- Lymphoma Diagnosis and Treatment 19
-
- Neuroblastoma Research and Treatments 7
- Co-authors
- Luke WhitesellLen NeckersL M NeckersMarta PillonLara MussolinO R ColamoniciL ZanescoE. Frascella
- Journals
- Leukemia (4 papers)Blood (3 papers)British Journal of Haematology (2 papers)International Journal of Oncology (2 papers)Haematologica (2 papers)
- Partner nations
- ItalyUnited StatesGermany
In The Last Decade
A Rosolen
44 papers receiving 927 citations
Peers
Comparison fields: 5 of 78
- Pathology and Forensic Medicine 317
- Immunology 252
- Neurology 161
- Oncology 263
- Genetics 87
Countries citing papers authored by A Rosolen
This map shows the geographic impact of A Rosolen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Rosolen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Rosolen more than expected).
Fields of papers citing papers by A Rosolen
This network shows the impact of papers produced by A Rosolen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Rosolen. The network helps show where A Rosolen may publish in the future.
Co-authors
The 25 scholars most cited alongside A Rosolen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 7 | |
| 3 | 2016 | 14 | |
| 4 | 2013 | 21 | |
| 5 | 2012 | 1 | |
| 6 | Risk-adapted therapy for patients with relapsed or refractory ALCL - interim-results of the prospective EICNHL-Trial ALCL-relapse | 2012 | 4 |
| 7 | 2012 | 4 | |
| 8 | 2010 | 57 | |
| 9 | 2009 | 8 | |
| 10 | 2005 | 18 | |
| 11 | 2005 | 70 | |
| 12 | 2003 | 23 | |
| 13 | 2002 | 7 | |
| 14 | Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. | 2001 | 63 |
| 15 | 1998 | 21 | |
| 16 | 1994 | 4 | |
| 17 | Antisense inhibition of CHP100 C-myc expression results in reduced in vitro growth kinetics and loss of in vivo tumorigenesis. | 1994 | 3 |
| 18 | 1993 | 14 | |
| 19 | Antisense inhibition of oncogene expression. | 1992 | 98 |
| 20 | 1990 | 45 |
About A Rosolen
A Rosolen is a scholar working on Pathology and Forensic Medicine, Neurology, Pulmonary and Respiratory Medicine, Oncology and Immunology, having authored 45 papers that have together received 956 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (19 papers), Sarcoma Diagnosis and Treatment (8 papers), Neuroblastoma Research and Treatments (7 papers), Immune Cell Function and Interaction (5 papers), Acute Lymphoblastic Leukemia research (5 papers), Virus-based gene therapy research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Viral-associated cancers and disorders (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (317 citations), Immunology (252 citations), Neurology (161 citations), Oncology (263 citations) and Genetics (87 citations). A Rosolen has collaborated with scholars based in Italy, United States and Germany. Frequent co-authors include Luke Whitesell, Len Neckers, L M Neckers, Marta Pillon, Lara Mussolin, O R Colamonici, L Zanesco, E. Frascella, Ralph Quinones and DG Poplack. Their work appears in journals such as Leukemia, Blood, British Journal of Haematology, International Journal of Oncology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.